title: Effect of Ligustrazine on liver injury after burn trauma.
abstract: This study was designed to investigate the effect of Ligustrazine on burn-induced liver injury as well as the activation of nuclear factor kappaB (NF-kappaB) in severely burned rats. Sprague-Dawley rats were divided into three groups: (1) sham group, rats who underwent sham burn; (2) control group, rats given third-degree burns over 30% total body surface area (TBSA) and lactated Ringer solution for resuscitation; (3) Ligustrazine group, rats given burn and lactated Ringer's solution with Ligustrazine inside for resuscitation. Liver injury was assessed at 24 h post-burn by serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), as well as liver wet/dry weight ratio. Liver myeloperoxidase (MPO) activity was also analyzed. Hepatic NF-kappaB activity was examined by electrophoretic mobility shift assay (EMSA). Burn results in hepatic dysfunction and increased hepatic NF-kappaB activity, elevated liver wet/dry ratio and hepatic MPO activity. Ligustrazine inhibited these changes and alleviated burn-mediated hepatic dysfunction. The data indicated that Ligustrazine has a protective effect on burn-induced liver injury and possible mechanism may be attributed to its inhibitory action on the activation of NF-kappaB following burn trauma.
authors.affiliation: Department of Pathophysiology, Anhui Medical University, and Department of Burns, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, People's Republic of China.
authors.forename: Hong
authors.initials: H
authors.lastname: Zheng
authors.forename: Xu-Lin
authors.initials: XL
authors.lastname: Chen
authors.forename: Zhi-Xun
authors.initials: ZX
authors.lastname: Han
authors.forename: Si-Ying
authors.initials: SY
authors.lastname: Wang
authors.forename: Zhi-Wu
authors.initials: ZW
authors.lastname: Chen
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002056:Burns / Q000150:complications / Q000188:drug therapy*; D008099:Liver / Q000293:injuries* / Q000378:metabolism; D008297:Male; D016328:NF-kappa B / Q000378:metabolism*; D009195:Peroxidase / Q000378:metabolism; D011719:Pyrazines / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016328:NF-kappa B; D011719:Pyrazines; D009195:Peroxidase; C017953:tetramethylpyrazine